October 15, 2025

9 October 2025 - New manufacturing facility to be located near Charlottesville, in Albemarle County, Virginia will develop and manufacture a broader range of medicines including weight management, metabolic and cancer technologies. Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America.

COLUMBIA, Md., (October 9, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Pre-Seed Builder Fund investment in JuneBrain. Under the umbrella of TEDCO’s Social Impact Funds, the Pre-Seed Builder Fund invests in and provides support to Maryland-based technology companies led by founders from economically underserved backgrounds.

“JuneBrain is dedicated to improving access to advanced retinal imaging in both...

Charlottesville, VA – September 29, 2025 – Luminoah, a MedTech company developing the first and only closed-loop personalized nutrition platform, today announced it has been named a finalist in MedTech Innovator’s (MTI) 2025 Early-Stage Grand Prize competition. This recognition comes as part of the culmination of the world’s largest accelerator for medical technology companies.

As a finalist, Luminoah will receive $25,000 in non-dilutive funding and compete for the top honor of the Early-Stage Grand Prize of $350,000 at The MedTech Conference, October 5–8, 2025, in San Diego, California. During...

BioHealth Innovation, Inc. (BHI) is excited to participate in TEDCO’s 11th Annual Entrepreneur Expo, taking place on Tuesday, October 21, 2025, at The Hotel at the University of Maryland in College Park, MD. The Expo is one of Maryland’s premier gatherings for entrepreneurs and innovators, bringing together over 1,000 of the region’s top business owners, investors, legislators, and industry influencers for a full day...

WASHINGTON (Oct. 7, 2025) — The George Washington University (GW) School of Medicine and Health Sciences, in partnership with Pfizer External Research and Grants, has announced two new opportunities to advance access to dermatologic care in underserved communities:

1. A Request for Applications (RFA) for innovative teledermatology projects focused on bridging disparities in the care of chronic inflammatory skin diseases such as atopic dermatitis and alopecia areata.
2. A Teledermatology Extension Award, offering $140,000 to one of the four past recipients of the GW/Pfizer Teledermatology Quality Improvement Grant, to continue and expand their successful programs.

In its first year, the GW/Pfizer Teledermatology Quality Improvement...

COLLEGE PARK, MD – October 7, 2025 – IonQ (NYSE: IONQ), the world’s leading quantum company, today announced the successful completion of its acquisition of Vector Atomic, the leading quantum sensing company based in California. The all-stock transaction significantly expands and rounds out IonQ’s quantum technology platform by adding the world’s most advanced precision atomic clocks, inertial sensors, and synchronization hardware to its industry-leading computing and networking stack.

Vector Atomic brings to IonQ over 75 employees, which include world-class scientists, engineers, and operators with deep experience delivering quantum-based positioning, navigation, and timing systems for space, submarine, and airborne applications. The company’s sensing technology delivers ultra-precise picosecond timing which is capable of delivering 1,000x improvement in GPS accuracy. 

Nov 2 - 4 at George Mason University in Virginia, and Organized in collaboration with George Mason University the Bridging Rare Summit 2025 will feature an exciting lineup of prominent speakers from India and the US, workshops, and a Gala dinner and Award Ceremony.

Join the Indo US Bridging RARE Summit 2025 — where global experts unite to advance patient-focused rare disease research. 

ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclinical-stage biotechnology company based in Seattle, Washington.

Moonlight Bio will deploy MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the scalable development and manufacturing of its T cell therapy pipeline.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Florida State University has selected GeneDx as one of its partners for the recently passed Sunshine Genetics Act, a groundbreaking initiative establishing the nation’s first state-backed genomic newborn screening (gNBS) program.

AstraZeneca’s decision to build a manufacturing plant in Albemarle County will accelerate research collaborations, bolster the area’s biotech industry and increase employment opportunities for University of Virginia graduates while enhancing the region’s growing reputation as a life science hub, University officials said.

The international pharmaceutical company announced Thursday it will build a factory in Albemarle County. The site is located near UVA’s North Fork, a research park that includes the nonprofit Cville Bio Hub’s Commonwealth BioAccelerator, which supports emerging biotechnology startups.

The plant will also be within a half-hour’s drive of UVA’s Paul and Diane Manning Institute of Biotechnology.

BARDA’s SPARK Hub for Innovations in Pediatrics is accepting applications for the 2026 SPARK Accelerator—a free, six-month program supporting innovators developing pediatric health security technologies. Participants receive expert mentorship, clinical access, and strategic connections through BioHealth Innovation’s Entrepreneur-in-Residence program. Applications are due November 17, 2025, with an informational webinar on October 29, 2025.

GERMANTOWN, Md., Oct. 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced long-term follow-up data demonstrating durable responses to PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of...